Lack of deleterious somatic mutations in the CD95 gene of plasmablasts from systemic lupus erythematosus patients and autoantibody‐producing cell lines

The interaction of CD95 with its ligand CD95L is important for negative selection of B cells during the germinal center (GC) reaction. Recently, mutations confering restistance to CD95‐induced apoptosis have been described for human GC B cells. Hence, as has been demonstrated for CD95‐deficient mice...

Full description

Saved in:
Bibliographic Details
Published in:European journal of immunology 2002-12, Vol.32 (12), p.3785-3792
Main Authors: Kurth, Julia, Perniok, Andreas, Schmitz, Roland, Iking‐Konert, Christof, Chiorazzi, Nicholas, Thompson, Keith M., Winkler, Thomas, Rajewsky, Klaus, Küppers, Ralf
Format: Article
Language:English
Subjects:
Autoantibodies - biosynthesis
B-Lymphocytes - immunology
Base Sequence
CD95
Cell Line
DNA - genetics
fas Receptor - genetics
Flow Cytometry
Genes, Immunoglobulin
Humans
Lupus Erythematosus, Systemic - genetics
Lupus Erythematosus, Systemic - immunology
Mutation
Plasma Cells - immunology
Plasmablast
Rheumatoid arthritis
Somatic mutation
Systemic lupus erythematosus
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The interaction of CD95 with its ligand CD95L is important for negative selection of B cells during the germinal center (GC) reaction. Recently, mutations confering restistance to CD95‐induced apoptosis have been described for human GC B cells. Hence, as has been demonstrated for CD95‐deficient mice, also GC‐derived autoreactive B cells carrying somatic CD95 gene mutations may potentionally survice negative selection and participate in the development of autoimmune diseases. Here, single plasmablasts (PB) which are implicated in the production of autoantibodies in systemic lupus erythematosus (SLE) patients as well as ten human B cell lines producing autoantibodies were analyzed for destructive somatic CD95 gene mutations. However, inactivating CD95 gene mutations were very rare in PB and not detected in the cell lines. Sequence analysis of V gene rearrangements amplified from single PB confirmed that the cells are (post) GC B cells and additionally demonstrated massive clonal expansion of these cells in two of four SLE patients. We conclude that CD95 gene mutations play little if any role in the generation of the pool of PB in SLE patients and that mutations in the CD95 gene are rare among autoantibody‐producing B cells in SLE and rheumatoid arthritis.
ISSN:0014-2980
1521-4141
DOI:10.1002/1521-4141(200212)32:12<3785::AID-IMMU3785>3.0.CO;2-E